Dolomite Bio RNAdia kit for single-cell research

Thursday, 30 September, 2021 | Supplied by: TrendBio Pty Ltd


Dolomite Bio has released the RNAdia kit for single-cell research. Together with the company’s Nadia platform, the kit offers a high-quality, complete solution for single-cell RNA sequencing. Researchers should be able to run more samples and choose the cell number and sequencing depth they truly need, in order to push the boundaries of single-cell research.

The flexibility of Dolomite Bio’s Nadia platform for high-throughput single-cell research, alongside the RNAdia kit and workflow, offers researchers the opportunity to study a wide range of unusual or large cell types, such as plants and cardiomyocytes. Nadia uses automation and flexibility to generate high-quality, reproducible single-cell data. Users can encapsulate up to eight samples, in parallel, in under 20 min, with over 50,000 single cells captured per cartridge in a run. Adding the Nadia Innovate to the Nadia Instrument transforms it into an open system, for the development of novel protocols and applications.

RNAdia also includes the option to purchase bioinformatic services, in the same way as one would a kit, providing easy access to expert data analysis without the need for an in-house bioinformatician. This provides a complete, seamless solution, from cells to data, in a workflow designed to take even less time than before. The kit thus aims to break down some of the barriers to single-cell research, such as compatibility and bioinformatic accessibility, which should enable researchers to spend more time making discoveries.

Online: www.trendbio.com.au
Phone: 1300 720 574
Related Products

Lumiprobe DusQ fluorescence quenchers

Lumiprobe offers a series of DusQ fluorescence quenchers with different spectral properties and...

Enzo Life Sciences SCREEN-WELL Epigenetics library

Enzo Life Sciences' SCREEN-WELL Epigenetics library contains 43 compounds with defined...

LSBio PathPlus Cancer Antibodies

The LSBio PathPlus Cancer series of antibodies include both well-established biomarkers of cancer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd